Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen's S1P Modulator License – A Good Deal Done Too Late?

This article was originally published in Scrip

Executive Summary

Biogen's license for the sphingosine 1-phosphate (S1P) receptor modulator MT-1303 from Mitsubishi Tanabe for up to $544m makes a lot of sense, but with four S1P-targeting drugs approved or in late-stage development did Biogen execute a good deal too late to catch up with the competition?

You may also be interested in...



ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports

The first round of third-quarter earnings reports for big pharmas quietly featured news about drug discontinuations and failures.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel